Combinations

Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (A) and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

• the Compound (A) has the structure:
• wherein:
• R1 is selected from the group consisting of hydrogen, halogen and a substituted or unsubstituted C1-C6 alkyl;
• Ring A is selected from the group consisting of a substituted or unsubstituted phenyl and a substituted or unsubstituted 5-6 membered monocyclic heteroaryl;
• Ring B is selected from the group consisting of a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl and a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl;
• R2 is selected from the group consisting of
• m is 0, 1, 2 or 3;
• R3 is selected from the group consisting of halogen and a substituted or unsubstituted C1-C6 alkyl;
• X is selected from the group consisting of hydrogen, halogen, hydroxy, cyano, a substituted or unsubstituted 4-6 membered monocyclic heterocyclyl, a substituted or unsubstituted amine(C1-C6 alkyl), a substituted or unsubstituted —NH—(CH2)1-6-amine, a mono-substituted amine, a di-substituted amine, an amino, a substituted or unsubstituted C1-C6 alkyl, a substituted or unsubstituted C1-C6 alkoxy, a substituted or unsubstituted C3-C6 cycloalkoxy, a substituted or unsubstituted (C1-C6 alkyl)acyl, a substituted or unsubstituted C-amido, a substituted or unsubstituted N-amido, a substituted or unsubstituted C-carboxy, a substituted or unsubstituted O-carboxy, a substituted or unsubstituted O-carbamyl and a substituted or unsubstituted N-carbamyl;
• Y is CH or N;
• Y1 is CR4A or N;
• Y2 is CR4B or N;
• Ring C is selected from the group consisting of a substituted or unsubstituted C6-C10 aryl, a substituted or unsubstituted monocyclic 5-10 membered heteroaryl, a substituted or unsubstituted monocyclic 5-7 membered carbocyclyl, a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl and a substituted or unsubstituted 7-10 membered bicyclic heterocyclyl;
• R4A and R4B are independently selected from the group consisting of hydrogen, halogen and an unsubstituted C1-4 alkyl;
• and
• R5 is a substituted or unsubstituted 5-7 membered monocyclic heterocyclyl;
• and
• the one or more of Compound (B) is a Bcl-2 inhibitor, or a pharmaceutically acceptable salt thereof;
• wherein the Bcl-2 inhibitor is selected from the group consisting of AGP-2575, AGP-1252, venetoclax
• navitoclax
• S55746/BCL201, S65487, BGB-11417, FCN-338 and AZD0466, or a pharmaceutically acceptable salts of any of the foregoing.